Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primaryEGFR mutation plus secondaryMET amplification and a novel acquired crizotinib-resistant mutationMET G1108C-Reference-Cited by-同舟云学术

Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primaryEGFR mutation plus secondaryMET amplification and a novel acquired crizotinib-resistant mutationMET G1108C

Published:2017-10 Issue:10 Volume:28 Page:2622-2624
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Li Y.Q.,Song S.S.,Jiang S.H.,Zhang X.Y.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/10/2622/20232574/mdx324.pdf

Reference3 articles.

1. MET amplification occurs with or without T790Mmutations inEGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib;Bean;Proc Natl Acad Sci USA,2007

2. Brief report: phase I results from a study of crizotinib in combination with erlotinibin patients with advanced non-squamous non-small cell lung cancer;Ignatius Ou;J Thorac Oncol,2017

3. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib;Pao;PLOS Med,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC;International Journal of Molecular Sciences;2023-08-23

2. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer;Drugs;2020-11-23

3. Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease;JCO Global Oncology;2020-11

4. Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report;Clinical Lung Cancer;2020-11

5. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report;Annals of Palliative Medicine;2020-09